bromantane
a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.
tier B · focus · 728 patients in the largest indexed Russian asthenia study
verdict
bromantane has a real Russian drug and human-study record for asthenia, but that record does not establish healthy cognitive enhancement, long-term safety, or the internet's preferred half-life number.
if you're asking whether bromantane is a peptide — no. bromantane, also called bromantan, is an adamantane-derived small-molecule CNS drug sold in Russia as Ladasten.
if you're asking whether it improves cognition in healthy people — that is not what the strongest clinical record establishes. the larger studies involved people diagnosed with asthenic disorders and measured antiasthenic and psychoautonomic outcomes.
if you're asking whether it is approved — it has an approved-drug history in Russia and is not FDA-approved. foreign approval is real regulatory context, not an FDA equivalence claim.
if you're asking what its half-life is — the frequently repeated 11.21-hour human figure was not traceable to an accessible primary concentration-time report in this review. a roughly seven-hour rat claim is also frequently miscited. the structured value stays null.
The clinical regimens below describe named Russian studies and populations. They are not recommendations for healthy use.
why B-tier
B-tier reflects a real approved-abroad drug history and multiple human studies, including a 728-patient multicenter asthenia report. It stays below A because the evidence is older, geographically concentrated, incompletely accessible, focused on diagnosed asthenia rather than healthy performance, and missing the kind of modern PK and long-term safety package expected for broad claims.
the core tension
Bromantane's foreign clinical record is substantial enough to reject the claim that it is pure internet lore. It is not broad enough to validate healthy-user cognition claims, chronic exposure, online-product quality, or the popular human half-life number.
what it is
Bromantane is N-(2-adamantyl)-N-(4-bromophenyl)amine, C16H20BrN, 306.24 g/mol, CAS 87913-26-6. It belongs to the adamantane chemical family and is described in Russian literature as an actoprotector or antiasthenic agent with stimulant and anxiolytic properties.
what it does
Animal work suggests changes in tyrosine hydroxylase and aromatic L-amino-acid decarboxylase expression, which can increase dopamine synthesis capacity rather than acting like a simple dopamine-reuptake blocker. Human mechanism is less complete. Clinical papers report symptom improvement in asthenic disorders, not a receptor-level proof of healthy performance enhancement.
origin
Bromantane was developed in the Soviet and Russian pharmacology tradition and later marketed as Ladasten for asthenic conditions. Much of the evidence is indexed in Russian-language journals, with limited replication under contemporary multinational trial standards.
why researchers are interested
Users are drawn to the combination of stimulation, lower subjective anxiety, and a story about increasing dopamine synthesis without classic stimulant dependence. The indexed clinical record supports an antiasthenic drug effect more directly than it supports that broader healthy-user narrative.
does it work
The human asthenia record is meaningful enough for B-tier and international-label confidence. General cognition, athletic performance, chronic use, internet-product quality, and modern safety surveillance remain much less certain.
claims vs the data
- bromantane improves asthenic symptoms — supported with limitations — older Russian clinical studies, including a 728-patient multicenter report, support that narrow indication.
- bromantane is proven for healthy cognitive enhancement — overreach — the healthy-volunteer record is tiny and acute; the larger evidence base concerns diagnosed asthenia.
- bromantane has an 11.21-hour verified human half-life — unsupported — the figure could not be traced to an accessible primary human PK report.
- Russian approval establishes the identity of online powder — contradicted — regulatory history applies to a regulated medicinal product, not an unverified internet supply chain.
key facts
- molecular formula: C16H20BrN
- molecular weight: 306.24 g/mol
- amino acids: n/a (small molecule, not a peptide)
- half-life: not structured; the repeated 11.21-hour human claim was not traced to an accessible primary PK source
- type: adamantane-derived CNS antiasthenic drug and WADA-listed stimulant
- CAS: 87913-26-6
- 728 patients in the largest indexed asthenia study
- 28 d duration of the two main indexed clinical reports
- 3% adverse-event rate reported in the 728-patient study
- unknown verified human terminal half-life in accessible primary data
frequently asked questions
What is bromantane?
Bromantane is an adamantane-derived CNS small molecule developed and marketed in Russia as Ladasten for asthenic disorders. It is not a peptide.
Does bromantane improve cognition?
Human studies support a narrower antiasthenic claim in diagnosed patients. Evidence for durable cognitive enhancement in healthy users is sparse.
What is bromantane's half-life?
No verified numeric value is published here. The widely repeated 11.21-hour figure was not traceable to an accessible primary human concentration-time report.
Is bromantane FDA-approved?
No. It has an approved-drug history in Russia but no FDA approval.
Is bromantane prohibited in sport?
Yes. WADA lists bromantan in the S6.A non-specified stimulant class, prohibited in competition.
related peptides
- Noopept (omberacetam; GVS-111) — another Russian-approved cognitive drug with a small human evidence base
- semax — a Russian neuroactive comparator with a different peptide mechanism and route
- selank — a Russian anxiolytic comparator rather than a stimulant
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
